THE WORLD’S LARGEST MEETING TO ACCELERATE …

MAY 9-12, 2022, HYNES CONVENTION CENTER, BOSTON

EARLY CONFIRMED KEYNOTES FOR TIDES 2022

THE WORLD’S LARGEST MEETING TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE PRODUCTS FROM EARLY DISCOVERY TO LATE-STAGE DEVELOPMENT & COMMERCIALIZATION

REGISTER BY DECEMBER 17TH AND SAVE $900 • WWW.TIDESEVENT.COM #TIDESUSA

Brett P. Monia, PhDChief Executive OfficerIonis Pharmaceuticals

Ugur Sahin, MDChief Executive OfficerBioNTech AG

Stéphane Bancel, MBAChief Executive OfficerModerna

2

TIDES is a ‘must-go’ conference for scientists working in the peptide/oligonucleotide area

THE INDUSTRY’S FLAGSHIP MEETING FOR OLIGONUCLEOTIDE AND PEPTIDE SCIENCE, TECHNOLOGY AND NETWORKING

“ ”George Wang, Analytical Chemist, Bristol-Myers Squibb

Accelerate your pipeline of oligonucleotide and peptide therapeutics to market by applying best practices and lessons learned from 125+ case studies and new data presentations from global industry leaders working across the entire spectrum of development and production.

Bring your product to market by meeting 90+ leading product and service providers showcasing live technology demonstrations in our exhibit hall.

Connect with 1300+ scientists and executives from 30 countries focused in oligonucleotide and peptide development and production during luncheons, cocktail receptions and networking breaks. Networking has never been easier with the included TIDES app that allows you to view the attendee list and schedule meetings before, during and after the event.

Register by December 17th and Save $900 • www.TIDESevent.com

SCIENCE TECHNOLOGY NETWORKING

ACCESS NOVEL SCIENCE ACROSS THE ENTIRE OLIGONUCLEOTIDE, PEPTIDE, AND mRNA SPECTRUMThe TIDES USA program features concurrent tracks covering the following 6 scientific themes including in-depth development strategies, trends, and technologies across the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing. Your registration provides access to the presentations across all tracks, allowing you to create your own customized agenda.

Oligonucleotide Chemistry, Manufacturing & Controls

Peptide Discovery, Preclinical and Clinical

Oligonucleotide Discovery, Preclinical and Clinical

mRNA Therapeutics/Vaccines & Genome Editing

Peptide Chemistry, Manufacturing & Controls

Drug Delivery Innovations

Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.

Explore new frontiers in peptide synthesis, discovery, design and engineering to improve targeting, delivery and drug-like properties. Case studies on the latest preclinical and clinical successes of peptides and peptide-like scaffolds and structures.

Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.

Hear updates on discovery strategies, clinical progress and CMC approaches for mRNA therapeutics and vaccines from industry-leading companies, and learn about state-of-the-art technologies for genome editing applications and hear about progress in genome editing delivery.

Improve process efficiencies and overcome challenges in process development, CMC and manufacturing. Understand regulatory expectations, new technologies and alternative approaches for emerging complex molecules.

Explore new technologies and approaches in the delivery of macromolecular therapeutics featuring multiple case studies of the delivery of oligonucleotides, peptides, mRNA therapeutics and genome editing delivery strategies. Learn about cutting-edge delivery advances including targeted delivery approaches for oligonucleotides, device-based delivery strategies and oral delivery of peptides.

3Register by December 17th and Save $900 • www.TIDESevent.com

Full-Day Training Course * 9:00am – 5:00pm

Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides from Early Development to Registration

Course Leader: Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma

Morning Half-Day Workshops • 8:00am-12:00pmWorkshop #1: Use of Scientific Tools to Support Accelerated Development of Oligonucleotide Therapeutics: Opportunities and Challenges

Workshop Co-Moderators:G. Susan Srivatsa, Ph.D., President, ElixinPharmaFran Wincott, Ph.D., Wincott & Associates, LLC

Workshop #2:How to Bring a Peptide Drug to Market from Discovery to Commercialization

Workshop Moderator: Trishul Shah, Director, Business Development and Head of Sales, North America, PolyPeptide Group

Workshop #3:

An Introduction to mRNA Technology: Discovery, Development, Delivery and CMC

Workshop Moderator TBA

Afternoon Half-Day Workshops • 1:00pm-5:00pmWorkshop #4: Managing Risks in Oligonucleotide Scale-up Manufacturing

Workshop Moderator: Doug Brooks, Ph.D., Principal Consultant, Matapalo LLC

Workshop #5: Peptide Drug Product Strategies: Analytical Characterization, Formulation and Fill-Finish

Workshop Moderator: Marc Jacob, Ph.D., Director of Business Development, Analytical Services, Ampac Analytical Laboratories Services

Workshop #6: LNP Formulations - Design, Synthesis, Chemistry and Manu-facturing of Lipids

Workshop Moderator TBA

Main Conference • Tuesday-Thursday, May 10-12, 2022

Keynote Speakers

Development of ASOsBrett P. Monia, Ph.D., Chief Executive Officer, Ionis Pharmaceuticals

Advances in Development of mRNAStéphane Bancel, Chief Executive Officer, Moderna

Advances in Development of Novel Therapeutics and VaccinesUgur Sahin, M.D., Chief Executive Officer, BioNTech AG, Germany

Pre-Conference Workshops and Training CourseMonday, May 9, 2022**Choose 1 Full Day Training Course OR 1 Morning + 1 Afternoon Workshop

PRELIMINARY AGENA (AS OF DECEMBER 3, 2021)


Oligonucleotide Sessions

Update on Wave’s ADAR Editing Platform and Preclinical AATD ProgramPaloma Giangrande, Ph.D., VP Platform Discovery Sciences, Biology, Wave Life Sciences

Oligonucleotides for CNS and Cardiometabolic DiseasesSession Chair: Elena Feinstein, M.D., Ph.D., Industry Expert and Consultant, Israel

Targeted Delivery of Conjugated siRNA/ASO to Specific Subsets of Neurons via Intranasal Administration Route for Treatment of Neurological and Psychiatric DisordersAnalía Bortolozzi Biassoni, Researcher, Neuroscience & Experimental Thera-peutics, Institute of Biomedical Research of Barcelona, Spain

Targeting Non-coding RNAs for Prevention of Post-Myocardi-al Infarction Heart Failure and for Treatment of Various Types of Cardiomyopathies Thomas Thum, M.D., Ph.D., CSO and Founder, Cardior Pharmaceuticals, Germany

New Technologies for Targeting RNA and Genomic DNA Session Chair: Punit Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals

RNA editing Howard Stern, M.D., Ph.D., Chief Scientific Officer, Korro Bio

Artificial IntelligenceAmit Deshwar, Vice President of Predictive Systems, Deep Genomics

DS DNA - Using Dervan Peptides to Target Genomic DNAAbhijit Bhat, Ph.D., Head of Research & Development, Design Therapeutics

Therapeutic Upregulation of Gene Transcription by Antisense Oligonucleotide Targeting of Regulatory RNAs; Long ncRNADavid Bumcrot, Ph.D., Chief Scientific Officer, CAMP4 Therapeutics

RNA Base Editing Gerard Platenburg, Chief Innovation Officer, ProQr Therapeutics, The Nether-lands

Characterization of Novel Exon-51 Skipping Oligonucleotides that Safely Rescues Dystrophin Expression in a Severe Model of Duchenne Muscular DystrophyMaria Hedlund, Ph.D., Senior Scientist, BioMarin Pharmaceutical

Antisense Oligonucleotide Therapeutics for Severe Genetic Epilepsies Using Human Cell-based ModelsGraham Dempsey, Ph.D., Chief Scientific Officer, Q-State Biosciences

Examples from Secarna’s Preclinical Anti-fibrotic and Immu-no-oncology PipelineFrank Jaschinski, Ph.D., Chief Scientific Officer, Secarna Pharmaceuticals, Germany

Small Activating RNA from Concept to Phase 2 Clinical TrialsNagy Habib, Head of R&D and CMO, MiNA Therapeutics, United Kingdom

mxRNA™: miniaturized RNAi Triggers Composed of Single OligonucleotidesDmitry Samarsky, Ph.D., Chief Technology Officer, Sirnaomics



Oligonucleotide Sessions (Continued)

Case Studies of Preclinical and Clinical Oligonucleotides in DevelopmentSession Chair: Troels Koch, Ph.D., Senior Vice President, Chemistry, MiNa Therapeutics

Preclinical and Clinical Oligonucleotide UpdateJennifer Lockridge, Ph.D., SVP, Program Development, Dicerna Pharmaceuti-cals, Inc. (Invited)

Regulatory Perspectives on Oligonucleotide TherapeuticsRao V. Kambhampati, Ph.D., Senior Regulatory Review Scientist, CDER Expert on CMC of Oligonucleotides, FDA (Invited)

Oligonucleotide CMC and Analytical StrategiesNitto Avecia Speaker TBA

CMC Regulatory Strategies for OligonucleotidesSession Chair: Thomas Rupp, Owner and Principal, Thomas Rupp Consulting AG, Germany

New Trends and CMC Strategies in Synthesis and Manufactur-ing of Long RNASession Chair: Yogesh Sanghvi, Ph.D., President, Rasayan, Inc.

Innovations in Synthesis for Long mRNA and Non-coding RNA Hari Pujar, Ph.D., Chief Operating Officer, Tessera Therapeutics

CMC and Manufacturing of Long RNAKristy Wood, Ph.D., Vice President, Nucleic Acid Therapeutics Development and Manufacturing, Intellia Therapeutics

Semi-automated Analysis of Oligonucleotide HPLC-UV/MS Data for Chemical Process Development Using Genedata Ex-pressionistTim Nagel, Ph.D., Scientist, PTDC – Analytical Research and Development / Hyphenated and Special Technologies, F. Hoffmann-La Roche, Switzerland

Flexibility Meets Efficiency: Platforms for Purity and Impurity Profiling of Synthetic Oligonucleotides in Early Drug Discovery Using Mass SpectrometryKathrin Stavenhagen, Ph.D., Senior Research Scientist, Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), Bio-Pharmaceuticals R&D, Astrazeneca, Sweden

New Approaches for Long RNADan Anderson, Founder, Orna Therapeutics

Synthesis and Manufacturing of Long RNADavid Butler, VP Chemistry, Korro Bio (Invited)

Endless RNADiego Miralles, CEO, Laronde (Invited)

Automation and Industry 4.0 Concepts in Commercial Manu-facturing of Oligonucleotides and PeptidesSession Chair: Trishul Shah, Director, Business Development and Head of Sales, North America, PolyPeptide Group

Industry 4.0 Manufacturing ConceptsBachem Speaker TBA



Oligonucleotide Sessions (Continued)RNAi Therapeutics for Cardiometabolic Disease: the Start of a New AgeJoshua R. Friedman, M.D., Ph.D., Senior Director, Clinical Research, Alnylam Pharmaceuticals U adaptorPeter Ghoroghchian, Ph.D., Co-Founder, President and CEO, Ceptur Therapeu-tics LGC’s Approach to Tackle a Complex Aptamer Manufacture: A Case StudyXibo Li, Ph.D. Associate Director, Oligonucleotide Process Development & Manufacturing, LGC

Peptide Sessions

Bicyclic Peptides (Bicycles), A New Anti-infective ModalityMichael Skynner, Ph.D., Chief Operating Officer, Bicycle Therapeutics, United Kingdom

Peptides (and Oligonucleotides) in Orphan IndicationsSession Chair: Bruce Morimoto, Ph.D., Vice President, Cerecin, USA

Developing Peptide Therapeutics Against GPCRsSession Chair: Rami Hannoush, Ph.D., Partner - US Ventures, Mubadala Cap-ital

GPCR Peptide TherapeuticsSri Kosuri, Co-founder and CEO, Octant (Invited)

Structural Biochemistry of GPCRsPatrick Scheerer, Ph.D. Professor, Charité – Universitätsmedizin Berlin, Ger-many (Invited)

Developing Peptide Therapeutics Against GPCRsPeter McNamara, Head of Research, Tectonic Therapeutics (Invited)

Peptide Agonists as TherapeuticsSession Chair: Rami Hannoush, Ph.D., Partner - US Ventures, Mubadala Cap-ital

Development of Therapeutic Peptide AgonistsSoren Ostergaard, Scientist, Novo Nordisk (Invited)Protein Engineering for Wnt Pathway Agonists for Therapeu-ticsYang Li, Ph.D., Senior Vice President, Biology, Surrozen

Learning Relationship between Chemical and Physical Stabili-ty of Peptides: Tools for Predicting Therapeutic Peptide Be-havior during Drug DevelopmentKatelyn Smith, Ph.D., Associate Principal Scientist, Merck & Co., Inc.

Peptide Agonists as TherapeuticsSachdev Sidhu, Founder, antlerA (Invited)

Next-generation Peptide Discovery PlatformsJigar Patel, Ph.D., Founder & CEO, Nimble Therapeutics




8

Peptide Sessions (Continued)

Next-Generation Peptide Libraries for DiscoveryRajinder Singh, CSO, Circle Pharma (Invited)

Peptide DiscoveryHiroaki Suga, Professor, University of Tokyo (Invited)

Theranostics, Radiopharmaceuticals& Tumor Imaging with PeptidesSession Chair: Ved Srivastava, Ph.D., Vice President of Peptide Chemistry, Intarcia Therapeutics

Peptide-Drug Conjugates as Tumor Targeted TherapiesSession Chair: Jesse Dong, Ph.D., Vice President, Peptide Chemistry, BioN-Tech

Delivering Immunotherapy to Tumors using an Engineered Peptide-Immunostimulant Conjugate Caitlyn Miller, Researcher, Stanford University

Update on the OncoFap Program Samuele Cazzamalli, Head of Small Molecule Therapeutics, Philogen

Peptide-Drug Conjugates Fredrik Lehmann, Head of R&D, Oncopeptides (Invited)

Peptide-Drug Conjugates Christian Marsolais, SVP and CMO, Theratechnologies (Invited)

Innovations in Peptide Therapeutic DiscoverySession Chair: Jesper Lau, Ph.D., Vice President, Chemical Biology, Novo Nordisk A/S, Denmark

Discovery and Optimization of the all-D-peptide Parkinson’s Disease Drug Candidate SVD-1 with Its α-synuclein Oligomer Disrupting Mode of ActionDieter Willbold, Ph.D., Director, Forschungszentrum Jülich, Germany

Peptide Nucleic Acid Manufacturing and Formulation: Unlock-ing the Promise in Rare DiseaseDietrich Stephan, Ph.D., CEO, NeuBase Therapeutics

Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal VaccineMichael Pennington, Ph.D., CSO, Ambiopharm

Peptide CMC and ManufacturingSession Chair: Christopher McGee, Ph.D., Senior Director, Business Develop-ment, BachemPeptide Therapeutic Technical Case Study Jon Holbech Rasmussen, Ph.D., Director, Global Development, PolyPeptide Group, Sweden

Peptide Manufacturing Case Study Bachem Speaker TBA

Tirzepatide, A Once-weekly Dual GIP and GLP-1 Receptor Ag-onist: CMC Considerations for Development of a High Volume Complex Synthetic Peptide Michael Kopach, Ph.D., Senior Research Advisor, Eli Lilly and Company



9

mRNA Therapeutics/Vaccines and Genome Editing Sessions

Programming mRNA for Cancer ImmunotherapyTasuku Kitada, Ph.D., President and Head of R&D, Strand Therapeutics (Invited)

Gram-Scale Good Manufacturing Practice (GMP) Single Guide RNA for CRISPR-based Gene EditingJoe Guiles, Ph.D., Head of Development, Agilent Technologies

mRNA in Infectious Diseases Session Chair: Andreas Kuhn, Ph.D., Senior Vice President RNA Biochemistry & Manufacturing, BioNTech RNA Pharmaceuticals GmbH, Germany

CMC Strategies for mRNAJames Thompson, Ph.D., CMC Therapeutic Area Lead, Moderna Therapeutics (Invited)

mRNAEric Marcusson, Ph.D., Co-Founder and CSO, Providence Therapeutics

Prime EditingJennifer Gori, Ph.D., Vice President, Research, Prime Medicine (Invited)

RNA EditingDong Wei CEO, EdiGene (Invited)

RNA EditingKen Prentice, VP, Head of Process and Product Development, Shape Thera-peutics, Inc.

Drug Delivery Strategies in Genome EditingSession Chair: Rubina Parmar, Ph.D., Senior Director, Chemistry and Delivery Sciences, Intellia Therapeutics

ATTR, Ex Vivo Program UpdateIntellia Therapeutics Speaker TBA

New Technologies in Genome EditingSession Chair: Cecilia Fernandez, Ph.D., VP of Strategic Planning and Opera-tions, Chroma Medicine

Improving Delivery Mechanisms in Gene editing with mRNA Technology Eric Huang, Ph.D., General Manager and Chief Scientific Officer, Moderna Genomics (Invited)

Base EditingNicole Gaudelli, Head of Genome Editing, Beam Therapeutics (Invited)

Emerging Editing TechnologiesJonathan Finn, CSO, Tome Bio (Invited)

Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA1Lisa Michaels, M.D., Executive Vice President and Chief Medical Officer, Edi-tas Medicine

In Vivo CRISPR Base Editing to Treat ASCVDAndrew Bellinger, M.D., Ph.D., Chief Scientific Officer, Verve Therapeutics



10

mRNA Therapeutics/Vaccines and Genome Editing Sessions (Continued)

CRISPR/Cas9-mediated Genome Editing in Mice: Results from 500 projectsLin Wu, Ph.D., Director, Genome Modification Facility, Harvard University

Exosomal DeliveryKonstantin Konstantinov, Manufacturing & Process Sciences Executive Vice President, Codiak Biosciences (Invited)

Delivery of CRISPR TherapeuticsTony Ho, EVP and Head of R&D, CRISPR Therapeutics (Invited)

Extra-Hepatic LNPsGaurav Sahay, Associate Professor, Pharmaceutical Sciences, Oregon State University Delivery Sessions

Novel Delivery Technologies for MacromoleculesSession Chair: Stephen T. Spagnol, Ph.D., Associate Director, Large Molecule Drug Product Development, Johnson & Johnson

Peptide ConjugatesAndy Boswell, Scientist, Genentech (Invited)

Peptide Conjugation and Reprogramming of CellsRami Hannoush, Ph.D., Partner – US Ventures, Mubadala Capital

Endosomal Escape Vehicle (EEV)-Conjugation Enhances Functional Delivery of OligonucleotidesLeo Qian, Ph.D., Co-founder and Vice President, Discovery Research, Entrada Therapeutics

Going Beyond GalNAc Conjugates: Challenges and Opportuni-ties in Targeted DeliverySession Chair: Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

An Overview of Emerging Trends in Drug DeliveryMuthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

Antibody-Oligo Conjugates and DeliveryArthur Levin, Ph.D., Chief Scientific Officer, Avidity Biosciences

Targeted Delivery of ASO TherapeuticsPunit Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis PharmaceuticalsFORCE(TM) Platform for Targeted Delivery of Oligonucleotide Therapeutics in Muscle DiseasesTimothy Weeden, Senior Director, Head of Platform Development, Dyne Ther-apeutics

The Design of Lipid Nanoparticles to Enable Delivery of Di-verse Nucleic Acid Payloads Beyond the HepatocytePeter Lutwyche, Ph.D., President & CEO, Genevant Sciences Corp., Canada



11

Delivery Sessions (Continued)

The Nanoprimer: A Nanoparticle Designed to the Efficacy of Nucleic Acid-based TherapeuticsJulie Devallière, Ph.D., Senior Team Leader, Biology, Curadigm, France

Development of an UV Spectroscopy-based Machine Learning Model to Characterize Lipid Nanoparticle Drug Delivery Sys-tem of Nucleic AcidsZhenqi (Pete) Shi, Ph.D., Principal Scientist, Genentech

Delivery of RNA Therapeutics: The Great Endosomal Escape!Steven Dowdy, Ph.D., Professor, Cellular and Molecular Medicine, UCSD School of Medicine


EXHIBITORSSPONSORSDIAMOND SPONSOR

EVENT SPONSORS

12

MEET THE PEOPLE BEHIND THE PRODUCTS & GET THE ANSWERS YOU NEED

Almac Group

Alturas Analytics

AM Chemicals

Aspen Pharma

BCN Peptides

Bio-Works Sweden

Biotage Sweden AB

Biotechlogic

Boston Analytical

CEM

CPC Scientific

Cytiva

DAISO Fine Chem

EMD Millipore Corporation

emp Biotech GmbH

EUROAPI

Evonik

GenePharma

Glen Research

RIBOBIO

Herbert Brown Pharma & Research

JenKem Technology

Kinovate Life Sciences

LGC, Biosearch Technologies

Lifecore Biomedical

Organix, Inc

Pace Analytical Life Sciences

Pall Corporation

Piramal Pharma Solutions

Shanghai Hongene Biotech Corporation

Singota Solutions

Symbiosis Pharmaceutical Services

Teledyne ISCO

Tosh Bioscience

Waters Corporation

YMC Process Technologies

For more information on how you can connect with key buyers at TIDES 2022, contact: A-H: Michael Dunnet, Phone: +1 (617) 960-6173 | E-mail: [email protected]

I-Z: Michael Moriarty, +1 (646) 895-7412 | E-mail: [email protected]

ONLINE:TIDESevent.com

CALL888-670-8200 OR+1-941-554-3500

WAYS TO REGISTER3 EMAIL

[email protected]

Also Consider Attending POSTER PRESENTATIONS GROUP DISCOUNTS:

AsiaTIDES 202214-16 September 2022Westin Miyako KyotoKyoto, Japan

TIDES Europe 202216-18 November 2022 AUSTRIA CENTER VIENNAVienna, Austria

Share your company’s latest research by presenting a poster at TIDES 2022. All posters are displayed inside the exhibit hall throughout the meeting. The deadline to submit a poster abstract is April 8, 2022.

Learn More & Submit Poster Abstract

Register a group of 3+ to receive additional savings.

To register your group, please contact:

Jessica Purnell

[email protected]

or +44 (0)20 7551 9521

13

2021 REGISTRATION AND PRICING

IN–PERSON PASS SAVE $900 Register by December 17, 2021

Industry Rates DISCOUNT STANDARD RATE

Main Conference + Pre-conference Workshop $2,899 $3,799

Main Conference Only $2,299 $3,199

Poster Presentation Add On $150

SAVE $250 Register by December 17, 2021

Academic/Govt Rates*Main Conference + Pre-conference Work-shop $1,149 $1,399

All Access Conference Pass $849 $1,099Poster Presentation Add On Free

*Academic/Government rates are only extended to full-time employees of government, universities and university-affiliated hospitals with no industry affiliation.

VIRTUAL PASS SAVE $500 Register by December 17, 2021

Industry Rates DISCOUNT STANDARD RATE

Digital Experience Pass + Workshop $2,499 $2,999

Digital Experience Pass $1,899 $2,399

Poster Presentation Add On $150

SAVE $250Register by December 17, 2021

Academic/Govt Rates*Digital Experience Pass + Workshop $1,249 $1,499

Digital Experience Pass $649 $899

Poster Presentation Add On Free

THE WORLD’S LARGEST MEETING TO ACCELERATE …

Documents

Transcript of THE WORLD’S LARGEST MEETING TO ACCELERATE …